MarketCapExport financials
Jazz Pharmaceuticals plc (JAZZ)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Jazz Pharmaceuticals plc Income Statement 2025-2008 | JAZZ
Brief overview of financial performance at Jazz Pharmaceuticals plc
The conclusions below are based on five years of reported results. Revenue reported by Jazz Pharmaceuticals plc was $2.4 billion at the beginning of the period and $4.3 billion at the end. The cumulative result was +80.6%, corresponding to roughly 12.5% per year. Top-line growth remained consistently strong over the period.
EBITDA was $397 million at the beginning and −$389 million at the end of the period (−198%). EBITDA underperformed the top-line trend. EBITDA margin moved from 16.8% to −9.1%. Cost pressure reduced operating profitability.
The final result was $239 million initially and −$356 million in the final year. The business lost profitability by the end of the period.
Market value was $9.4 billion at the start and $10.5 billion at the end. Market value lagged the financial performance.
What the figures show
Signs of deterioration dominate the five-year picture. The strongest signals are revenue expansion. The overall view is constrained by a narrow EBITDA buffer, pressure on operating profitability and a weaker final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Jazz Pharmaceuticals plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
10.5 B | 8.9 B | 8.22 B | 8.79 B | 8.2 B | 9.36 B | 8.36 B | 7.68 B | 9.19 B | 7.38 B | 8.12 B | 10.6 B | 9.64 B | 3.43 B | 2.19 B | 275 M | 30 M | - |
Shares |
61 M | 61.8 M | 63.3 M | 62.5 M | 59.7 M | 55.7 M | 57.6 M | 61.2 M | 61.3 M | 61.9 M | 63 M | 62.6 M | 61.6 M | 60.2 M | 46.8 M | 36.3 M | 30 M | - |
Historical Prices |
173 | 144 | 130 | 141 | 137 | 168 | 115 | 140 | 145 | 133 | 122 | 170 | 152 | 58.2 | 52.5 | 7.57 | 1 | 7.88 |
Net Income |
-356 M | 560 M | 415 M | -224 M | -330 M | 239 M | 523 M | 447 M | 488 M | 397 M | 330 M | 58.4 M | 216 M | 289 M | 125 M | 37.5 M | -6.84 M | - |
Revenue |
4.27 B | 4.07 B | 3.83 B | 3.66 B | 3.09 B | 2.36 B | 2.16 B | 1.89 B | 1.62 B | 1.49 B | 1.32 B | 1.17 B | 872 M | 586 M | 272 M | 83.5 M | 128 M | - |
Gross Profit |
- | - | - | - | - | 611 M | 2.03 B | 1.77 B | 1.51 B | 1.38 B | 1.22 B | 1.06 B | 770 M | 508 M | 258 M | 77.1 M | - | - |
Operating Income |
-430 M | 717 M | 579 M | -65.5 M | 170 M | 378 M | 532 M | 615 M | 529 M | 592 M | 508 M | 196 M | 340 M | 198 M | 128 M | 57.8 M | 15.9 M | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | 1.44 M | 8.68 M | -1.7 M | - | 1.68 M | 12.7 M | 22.8 M | - |
EBITDA |
-389 M | 749 M | 609 M | -35.2 M | 197 M | 397 M | 903 M | 830 M | 694 M | 705 M | 599 M | 329 M | 419 M | 272 M | 134 M | 58.7 M | 17.4 M | - |
Operating Expenses |
- | - | - | - | - | 233 M | 1.39 B | 1.11 B | 895 M | 767 M | 683 M | 618 M | 430 M | 310 M | 131 M | 116 M | 113 M | - |
General and Administrative Expenses |
1.81 B | 1.39 B | 1.34 B | 1.42 B | 1.45 B | 854 M | 737 M | 684 M | 544 M | 501 M | 447 M | 404 M | 303 M | 224 M | 109 M | 69 M | 58.7 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Jazz Pharmaceuticals plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
64.7 M | 63.2 M | 61.9 M | - | 60.7 M | 61.2 M | 61 M | - | 61.4 M | 62.9 M | 62.5 M | - | 63.1 M | 64 M | 63.5 M | - | 62.8 M | 62.4 M | 61.9 M | 61.6 M | 61.3 M | 59.4 M | 56.5 M | 75 M | 55.5 M | 55.4 M | 56 M | -111 K | 56.7 M | 56.7 M | 57.2 M | 57.7 M | 60.5 M | 60.2 M | 59.9 M | 58.9 M | 60.1 M | 60.1 M | 59.9 M | 59.8 M | 60.4 M | 60.5 M | 61.1 M | 61.3 M | 61.4 M | 61.2 M | 60.8 M | 60.6 M | 60.3 M | 59.5 M | 58.5 M | 57.9 M | 58.2 M | 58.7 M | 58.4 M | 58 M | 57.7 M | 57 M | 53.9 M | 42.5 M | 42 M | 41.2 M | 40.4 M |
Net Income |
-483 M | 193 M | 293 M | - | 251 M | -718 M | -92.5 M | - | 215 M | 169 M | -14.6 M | - | 147 M | 104 M | 69.4 M | - | -19.6 M | 34.7 M | 1.65 M | - | -52.8 M | -363 M | 122 M | 133 M | 148 M | 115 M | -158 M | 74 M | 102 M | 262 M | 85.2 M | 159 M | 149 M | 92.3 M | 46 M | 232 M | 63.5 M | 106 M | 86.5 M | 117 M | 89.8 M | 115 M | 75.8 M | 82.8 M | 88 M | 88.1 M | 70.7 M | 81.6 M | 25.8 M | 43.7 M | -92.6 M | 55.3 M | 75.4 M | 42.2 M | 43.4 M | 201 M | 33.2 M | 27.1 M | 27.7 M | 37.5 M | 32.5 M | 33.2 M | 21.8 M |
Revenue |
1.24 B | 1.21 B | 1.07 B | - | 1.13 B | 1.05 B | 898 M | - | 1.05 B | 1.02 B | 902 M | - | 972 M | 957 M | 893 M | - | 941 M | 933 M | 814 M | - | 838 M | 752 M | 608 M | 666 M | 601 M | 562 M | 535 M | 582 M | 538 M | 534 M | 508 M | 476 M | 469 M | 500 M | 445 M | 436 M | 412 M | 394 M | 376 M | 397 M | 374 M | 381 M | 336 M | 341 M | 341 M | 334 M | 309 M | 328 M | 307 M | 291 M | 247 M | 236 M | 232 M | 208 M | 196 M | 184 M | 176 M | 124 M | 103 M | 83.5 M | 73.3 M | 64.6 M | 50.9 M |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 611 M | 555 M | 530 M | 502 M | 541 M | 501 M | 496 M | 470 M | 441 M | 439 M | 461 M | 407 M | 405 M | 377 M | 361 M | 349 M | 359 M | 347 M | 355 M | 310 M | 315 M | 310 M | 310 M | 279 M | 295 M | 277 M | 258 M | 214 M | 208 M | 206 M | 182 M | 167 M | 156 M | 142 M | 111 M | 93.7 M | 77.1 M | 68.3 M | 60.1 M | 47.1 M |
Operating Income |
-413 M | 248 M | 337 M | - | 57.5 M | -686 M | -55.9 M | - | 260 M | 199 M | 66.2 M | - | 172 M | 158 M | 126 M | - | 24.8 M | 85.5 M | 87.5 M | - | 28.4 M | -69.6 M | 162 M | 173 M | 196 M | 198 M | -190 M | 61.2 M | 133 M | 204 M | 134 M | - | 189 M | 153 M | 87.8 M | - | 86.5 M | 165 M | 136 M | - | 136 M | 169 M | 121 M | - | 132 M | 153 M | 117 M | - | 58 M | 74.3 M | -66.7 M | - | 101 M | 77.1 M | 68.2 M | - | 55.3 M | 39.4 M | 35.7 M | - | 33.7 M | 33.9 M | 22.6 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.46 M | - | -749 K | - | -819 K | - | -977 K | -1.91 M | 2.24 M | - | - | - | - | - | - | - | - | - | - | - | 58 K | - | 129 K | 659 K | 777 K |
EBITDA |
-242 M | 266 M | 346 M | - | 226 M | -524 M | -45.5 M | - | 418 M | 355 M | 73.9 M | - | 327 M | 310 M | 134 M | - | 166 M | 234 M | 95.2 M | - | 47.8 M | 70.9 M | 167 M | 240 M | 263 M | 261 M | -127 M | 235 M | 196 M | 266 M | 191 M | - | 200 M | 161 M | 91.5 M | - | 95.7 M | 171 M | 139 M | - | 144 M | 174 M | 124 M | - | 139 M | 158 M | 119 M | - | 63.1 M | 77.5 M | -65.4 M | - | 103 M | 78.2 M | 68.8 M | - | 56.1 M | 39.8 M | 35.9 M | - | 34 M | 34 M | 22.7 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -85.5 M | - | - | - | - | - | 438 M | 359 M | 332 M | 691 M | 480 M | 368 M | 291 M | 336 M | 441 M | 281 M | 347 M | 357 M | 405 M | 325 M | 229 M | 240 M | 359 M | 238 M | 212 M | 215 M | 315 M | 209 M | 180 M | 193 M | 295 M | 249 M | 217 M | 314 M | 208 M | 132 M | 131 M | 128 M | 156 M | 120 M | 84.8 M | 66.8 M | 77.1 M | 39.6 M | 30.7 M | 28.3 M |
General and Administrative Expenses |
408 M | 389 M | 353 M | - | 531 M | 358 M | 514 M | - | 326 M | 339 M | 352 M | - | 308 M | 341 M | 298 M | - | 358 M | 366 M | 309 M | - | 364 M | 429 M | 261 M | 247 M | 207 M | 191 M | 208 M | 214 M | 179 M | 176 M | 168 M | - | 156 M | 159 M | 207 M | - | 125 M | 132 M | 144 M | - | 124 M | 123 M | 129 M | - | 104 M | 107 M | 112 M | - | 93.5 M | 101 M | 106 M | - | 75 M | 77.5 M | 70.5 M | - | 60.9 M | 57.2 M | 44.4 M | - | 30.5 M | 22.1 M | 19.9 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Jazz Pharmaceuticals plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Israel
Canada
Schweiz
Australia
Britain
Russia
India
